Combo therapies featuring an immunotherapy and a tyrosine kinase inhibitor (TKI) are all the rage at this year’s annual congress of the European Society of Medical Oncology (ESMO).
This type of combination has proven effective in a range of cancer indications, including in kidney cancer, with Merck & Co’s (NYSE: MRK) superstar checkpoint blocker Keytruda (pembrolizumab) attracting the most attention.
This year Merck is facing competition in that indication, as well as in gastric cancer, where Keytruda has been paired with a unique oral TKI, Lenvima (lenvatinib), from Japan’s Eisai (TYO: 4523), in the LEAP studies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze